Literature DB >> 17728707

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.

W N Suki1, R Zabaneh, J L Cangiano, J Reed, D Fischer, L Garrett, B N Ling, S Chasan-Taber, M A Dillon, A T Blair, S K Burke.   

Abstract

Elevated serum phosphorus and calcium are associated with arterial calcification and mortality in dialysis patients. Unlike calcium-based binders, sevelamer attenuates arterial calcification but it is unknown whether sevelamer affects mortality or morbidity. In a multicenter, randomized, open-label, parallel design trial we compared sevelamer and calcium-based binders on all-cause and cause-specific mortality (cardiovascular, infection, and other) in prevalent hemodialysis patients. A total of 2103 patients were initially randomized to treatment and 1068 patients completed the study. All-cause mortality rates and cause-specific mortality rates were not significantly different. There was a significant age interaction on the treatment effect. Only in patients over 65 years of age was there a significant effect of sevelamer in lowering the mortality rate. There was a suggestion that sevelamer was associated with lower overall, but not cardiovascular-linked, mortality in older patients. We suggest that further research is needed to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17728707     DOI: 10.1038/sj.ki.5002466

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  122 in total

Review 1.  Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.

Authors:  Kamyar Kalantar-Zadeh; Anuja Shah; Uyen Duong; Rulin C Hechter; Ramanath Dukkipati; Csaba P Kovesdy
Journal:  Kidney Int Suppl       Date:  2010-08       Impact factor: 10.545

2.  Should glucose-sparing prescriptions be expected to reduce the cardiovascular risk of peritoneal dialysis patients?

Authors:  Rajnish Mehrotra; Ian H de Boer
Journal:  J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 10.121

Review 3.  Strategies for postmarketing surveillance of drugs and devices in patients with ESRD undergoing dialysis.

Authors:  Moshe Vardi; Robert W Yeh; Charles A Herzog; Wolfgang C Winkelmayer; Soko Setoguchi; David M Charytan
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-22       Impact factor: 8.237

Review 4.  Evidence-based cardiology in hemodialysis patients.

Authors:  Michael Allon
Journal:  J Am Soc Nephrol       Date:  2013-10-17       Impact factor: 10.121

5.  Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.

Authors:  Hirotaka Komaba; Mia Wang; Masatomo Taniguchi; Suguru Yamamoto; Takanobu Nomura; Douglas E Schaubel; Abigail R Smith; Jarcy Zee; Angelo Karaboyas; Brian Bieber; Masafumi Fukagawa; Francesca Tentori
Journal:  Clin J Am Soc Nephrol       Date:  2017-07-19       Impact factor: 8.237

Review 6.  [Mineral and bone disorder in chronic kidney disease : Critical appraisal of pharmacotherapy].

Authors:  R Brunkhorst
Journal:  Internist (Berl)       Date:  2014-03       Impact factor: 0.743

7.  Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis.

Authors:  Julia Spoendlin; Julie M Paik; T Tsacogianis; Seoyoung C Kim; Sebastian Schneeweiss; Rishi J Desai
Journal:  JAMA Intern Med       Date:  2019-06-01       Impact factor: 21.873

Review 8.  Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.

Authors:  Caroline M Perry; Greg L Plosker
Journal:  Drugs       Date:  2014-05       Impact factor: 9.546

9.  Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.

Authors:  Mario Cozzolino; Maria Antonietta Rizzo; Andrea Stucchi; Daniele Cusi; Maurizio Gallieni
Journal:  Ther Adv Chronic Dis       Date:  2012-03       Impact factor: 5.091

10.  Serum phosphorus and mortality in the Third National Health and Nutrition Examination Survey (NHANES III): effect modification by fasting.

Authors:  Alex R Chang; Morgan E Grams
Journal:  Am J Kidney Dis       Date:  2014-06-14       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.